Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis

Journal of Biological Chemistry

Volumn 289, Issue 37, 2014, Pages 25812-25821

  Li, Liangwei ^a   Zhang, Yinwei ^a   Qiao, Jingjuan ^a   Yang, Jenny J ^a   Liu, Zhi Ren ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CELL PROLIFERATION; DISEASES; ENDOTHELIAL CELLS; ENZYMES; TUMORS;

BLOOD CIRCULATION; CANCER PATIENTS; DIAGNOSTIC MARKERS; PHYSIOLOGICAL FUNCTIONS; PYRUVATE KINASE; TUMOR ANGIOGENESIS; TUMOR GROWTH; TUMOR PROGRESSIONS;

DIAGNOSIS;

DIMER; PYRUVATE KINASE; PYRUVATE KINASE M2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; ISOPROTEIN; MEMBRANE PROTEIN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CIRCULATION; COLON CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN FUNCTION; TUMOR PROMOTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BLOOD; CELL MOTION; DRUG SCREENING; GENETICS; GLYCOLYSIS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CARRIER PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GLYCOLYSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; THYROID HORMONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907168819     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.576934     Document Type: Article

References (23)

1. Boros, L. G., Cascante, M., and Lee, W. N. (2002) Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov. Today 7, 364-372
2. Elbers, J. R., van Unnik, J. A., Rijksen, G., van Oirschot, B. A., Roholl, P. J., Oosting, J., and Staal, G. E. (1991) Pyruvate kinase activity and isozyme composition in normal fibrous tissue and fibroblastic proliferations. Cancer 67, 2552-2559
3. Hacker, H. J., Steinberg, P., and Bannasch, P. (1998) Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 19, 99-107
4. Dombrauckas, J. D., Santarsiero, B. D., and Mesecar, A. D. (2005) Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417-9429
5. Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J. K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., Yang, H., Mattaini, K. R., Metallo, C. M., Fiske, B. P., Courtney, K. D., Malstrom, S., Khan, T. M., Kung, C., Skoumbourdis, A. P., Veith, H., Southall, N., Walsh, M. J., Brimacombe, K. R., Leister, W., Lunt, S. Y., Johnson, Z. R., Yen, K. E., Kunii, K., Davidson, S. M., Christofk, H. R., Austin, C. P., Inglese, J., Harris, M. H., Asara, J. M., Stephanopoulos, G., Salituro, F. G., Jin, S., Dang, L., Auld, D. S., Park, H. W., Cantley, L. C., Thomas, C. J., and Vander Heiden, M. G. (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839-847
6. Jiang, J. K., Boxer, M. B., Vander Heiden, M. G., Shen, M., Skoumbourdis, A. P., Southall, N., Veith, H., Leister, W., Austin, C. P., Park, H. W., Inglese, J., Cantley, L. C., Auld, D. S., and Thomas, C. J. (2010) Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 20, 3387-3393
7. Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., and Cantley, L. C. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233
8. Gao, X., Wang, H., Yang, J. J., Liu, X., and Liu, Z. R. (2012) Pyruvate kinase m2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45, 598-609
9. Lee, J., Kim, H. K., Han, Y. M., and Kim, J. (2008) Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 40, 1043-1054
10. Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., and Semenza, G. L. (2011) Pyruvate kinase M2 is a PHD3- stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732-744
11. Vander Heiden, M. G., Locasale, J. W., Swanson, K. D., Sharfi, H., Heffron, G. J., Amador-Noguez, D., Christofk, H. R., Wagner, G., Rabinowitz, J. D., Asara, J. M., and Cantley, L. C. (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499
12. Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., and Lu, Z. (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480, 118-122
13. Weinberger, R., Appel, B., Stein, A., Metz, Y., Neheman, A., and Barak, M. (2007) The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur. J. Cancer Care (Engl) 16, 333-337
14. Ahmed, A. S., Dew, T., Lawton, F. G., Papadopoulos, A. J., Devaja, O., Raju, K. S., and Sherwood, R. A. (2007) M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur. J. Gynaecol. Oncol. 28, 83-88
15. Schneider, J. (2006) Tumor markers in detection of lung cancer. Adv. Clin. Chem. 42, 1-41
16. Ugurel, S., Bell, N., Sucker, A., Zimpfer, A., Rittgen, W., and Schadendorf, D. (2005) Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int. J. Cancer 117, 825-830
17. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., and Cantley, L. C. (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186
18. Mazurek, S. (2007) Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst. Schering Found. Symp. Proc. 4, 99-124
19. Hugo, F., Fischer, G., and Eigenbrodt, E. (1999) Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res. 19, 2753-2757
20. Wechsel, H. W., Petri, E., Bichler, K. H., and Feil, G. (1999) Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res. 19, 2583-2590
21. Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T. W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., Xie, J., Gu, T. L., Polakiewicz, R. D., Roesel, J. L., Boggon, T. J., Khuri, F. R., Gilliland, D. G., Cantley, L. C., Kaufman, J., and Chen, J. (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal 2, ra73
22. Hathurusinghe, H. R., Goonetilleke, K. S., and Siriwardena, A. K. (2007) Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann. Surg. Oncol. 14, 2714-2720
23. Duan, H. F., Hu, X. W., Chen, J. L., Gao, L. H., Xi, Y. Y., Lu, Y., Li, J. F., Zhao, S. R., Xu, J. J., Chen, H. P., Chen, W., and Wu, C. T. (2007) Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. J. Natl. Cancer Inst. 99, 1551-1555